Hyphen Pharma’s profit sinks 66.3% in H1

This was amidst a decrease in revenue.

Hyphens Pharma International Limited’s net profit after tax declined by 66.3% year on year to $2m during the first half of the year, amidst a decrease in revenue.

The 18.9% YoY decline in revenue in the Pharmaceutical and Medical Aesthetics segment was mainly due to lower sales in Vietnam.

Moreover, the Digital Platform and E-Pharmacy segment saw a YoY decrease of 5.9% to $20.4m.

However, the Proprietary Brands segment grew by 22.5% YoY to $17.4m, with the expansion of its portfolio, and higher demand for Ceradan® dermatological products and Ocean Health® health supplements.

Basic earnings per share stood at $0.54.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia